Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
4(27%)
Results Posted
86%(6 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_1
6
40%
Ph phase_2
6
40%
Ph phase_3
3
20%

Phase Distribution

6

Early Stage

6

Mid Stage

3

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
6(40.0%)
Phase 2Efficacy & side effects
6(40.0%)
Phase 3Large-scale testing
3(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

4

trials recruiting

Total Trials

15

all time

Status Distribution
Active(6)
Completed(7)
Terminated(1)
Other(1)

Detailed Status

Completed7
Not yet recruiting2
Recruiting2
Active, not recruiting2
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
4
Success Rate
87.5%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (40.0%)
Phase 26 (40.0%)
Phase 33 (20.0%)

Trials by Status

completed747%
not_yet_recruiting213%
recruiting213%
unknown17%
active_not_recruiting213%
terminated17%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT07722611Phase 2

A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)

Not Yet Recruiting
NCT06456346Phase 3

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

Active Not Recruiting
NCT06079879Phase 3

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Active Not Recruiting
NCT05558696Phase 2

A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)

Completed
NCT04254978Phase 2

Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

Completed
NCT06351631Phase 3

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

Recruiting
NCT07049939Phase 1

A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)

Completed
NCT07424950Phase 2

Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis

Not Yet Recruiting
NCT05597306Phase 1

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
NCT05223920Phase 2

An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

Completed
NCT06596668Phase 1

Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)

Completed
NCT05191797Phase 1

Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer

Terminated
NCT03136185Phase 1

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Completed
NCT02842827Phase 1

A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)

Completed
NCT05569538Phase 2

Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis

Unknown

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15